Pleco Therapeutics, a clinical-stage biopharmaceutical company developing novel therapies for difficult-to-treat cancers, has announced a positive outcome from its Pre-Investigational New Drug (Pre-IND) meeting with the US Food and Drug Administration (FDA).   The meeting addressed the continued development of PTX-252, an intravenous (IV) formulation designed to treat patients with acute myeloid leukaemia (AML).  The pre-IND […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!